
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
CureDuchenne has announced that they will contribute patient-level clinical data for treating muscular dystrophy to the Vivli platform. The data will supplement existing studies that are available to request on the Vivli platform and be available to other researchers around the world.
For more information, click






